International Stem Cell CORP director Maier Paul V sold 32,802 shares at $0.32 per share on September 11, 2026, in an SEC-coded S transaction. The sale represented about 100.0% of his prior holding and left him with no shares, giving investors a specific change in the director’s reported ownership.
Key Highlights
- The filing reports SEC transaction code S for the sale.
- Maier Paul V’s post-transaction holding was no shares in International Stem Cell CORP.
- The transaction took place on September 11, 2026.
International Stem Cell CORP (OTC: ISCO) saw a director sell 32,802 shares at $0.32 per share on September 11, 2026. The sale represented about 100.0% of that director’s prior holding, leaving no shares afterward.
Open-Market Sale by Maier Paul V
Maier Paul V was the director involved in the transaction. The sale carried SEC transaction code S. The transaction was reported through a Form 4. International Stem Cell CORP’s reported ownership change leaves Maier Paul V with no shares following the transaction. The disclosed percentage indicates that the sale covered his entire prior holding. Transaction code S denotes an open-market or private sale.
FAQs
Q: What did Maier Paul V sell in International Stem Cell CORP?
A: Maier Paul V sold International Stem Cell CORP shares in an SEC-reported transaction. The sale was classified with transaction code S.
Q: How many International Stem Cell CORP shares did the director sell?
A: The director sold 32,802 International Stem Cell CORP shares in the reported transaction. The filing lists a transaction price of $0.32 per share.
Q: When did the International Stem Cell CORP director transaction occur?
A: The transaction occurred on September 11, 2026, according to the filing. The reported sale represented about 100.0% of Maier Paul V’s prior share holding, and he owned 0 shares afterward.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.